Jagsonpal Pharmaceuticals Limited (BOM:507789)
210.55
+0.65 (0.31%)
At close: Nov 14, 2025
Jagsonpal Pharmaceuticals Revenue
Jagsonpal Pharmaceuticals had revenue of 744.65M INR in the quarter ending September 30, 2025, a decrease of -0.30%. This brings the company's revenue in the last twelve months to 2.83B, up 24.60% year-over-year. In the fiscal year ending March 31, 2025, Jagsonpal Pharmaceuticals had annual revenue of 2.69B with 28.76% growth.
Revenue (ttm)
2.83B
Revenue Growth
+24.60%
P/S Ratio
4.99
Revenue / Employee
2.02M
Employees
1,399
Market Cap
14.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 2.69B | 600.14M | 28.76% |
| Mar 31, 2024 | 2.09B | -280.12M | -11.83% |
| Mar 31, 2023 | 2.37B | 191.30M | 8.79% |
| Mar 31, 2022 | 2.18B | 296.38M | 15.77% |
| Mar 31, 2021 | 1.88B | 293.78M | 18.53% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 10.00T |
| Life Insurance Corporation of India | 9.14T |
| State Bank of India | 3.57T |
| Larsen & Toubro | 2.76T |
| HDFC Bank | 2.68T |
| Tata Consultancy Services | 2.58T |
| Bharti Airtel | 1.95T |
| ICICI Bank | 1.91T |
Jagsonpal Pharmaceuticals News
- 13 days ago - Q2 2026 Jagsonpal Pharmaceuticals Ltd Earnings Call Transcript - GuruFocus
- 14 days ago - Jagsonpal Pharmaceuticals shares decline nearly 3% today as revenue and EBITDA soften in Q2 - Business Upturn
- 9 months ago - Jagsonpal Pharmaceuticals shares drop 2.6% after USFDA issues warning letter for manufacturing lapses at API plant - Business Upturn
- 9 months ago - Jagsonpal Pharmaceuticals acquires Resilient Cosmeceuticals’ India business for Rs 24 crore - Business Upturn
- 10 months ago - Jagsonpal Pharmaceuticals shares jump nearly 6% on strong Q3 FY25 results - Business Upturn